SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
CancerRespiratory

PUBLISHER: Grand View Research | PRODUCT CODE: 2151800

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 2151800

Non-small Cell Lung Cancer Therapeutics Market Size, Share & Trends Analysis Report By Type, By Treatment, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Non-small Cell Lung Cancer Therapeutics Market Summary

The global non-small cell lung cancer therapeutics market size was valued at USD 24.1 billion in 2025 and is projected to grow from USD 27.1 billion in 2026 to USD 63.5 billion by 2033, at a CAGR of 12.9% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 35.4% in 2025. NSCLC remains the most common form of lung cancer, accounting for nearly 85% of all lung cancer cases worldwide.

The treatment landscape has shifted from conventional chemotherapy toward targeted therapies and immune checkpoint inhibitors, supported by updated clinical guidelines and broader molecular profiling in routine practice. Earlier diagnosis through screening programs in selected countries is also increasing the number of patients receiving treatment at earlier disease stages. However, treatment costs, unequal access to molecular diagnostics, and differences in healthcare infrastructure across regions continue to affect therapy adoption. Ongoing clinical research and regulatory approvals are expanding treatment options and supporting sustained market development.

Global Non-small Cell Lung Cancer Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global non-small cell lung cancer therapeutics market report based on type, treatment, distribution channel, and region:

  • Type Outlook (Revenue, USD Billion, 2021 - 2033)
  • Squamous Cell Carcinoma
  • Large Cell Carcinoma
  • Adenocarcinoma
  • Others
  • Treatment Outlook (Revenue, USD Billion, 2021 - 2033)
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Others
  • Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospital Pharmacy
  • Drug Store and Retail Pharmacy
  • Online Pharmacy
  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
Show more
Product Code: GVR-1-68038-703-2

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Treatment
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Non-small Cell Lung Cancer Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Non-small Cell Lung Cancer Therapeutics Market: Type Business Analysis

  • 4.1. Type Market Share, 2025 & 2033
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Billion)
  • 4.4. Squamous Cell Carcinoma
    • 4.4.1. Squamous Cell Carcinoma Market, 2021 - 2033 (USD Billion)
  • 4.5. Large Cell Carcinoma
    • 4.5.1. Large Cell Carcinoma Market, 2021 - 2033 (USD Billion)
  • 4.6. Adenocarcinoma
    • 4.6.1. Adenocarcinoma Market, 2021 - 2033 (USD Billion)
  • 4.7. Others
    • 4.7.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 5. Non-small Cell Lung Cancer Therapeutics Market: Treatment Business Analysis

  • 5.1. Treatment Market Share, 2025 & 2033
  • 5.2. Treatment Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Billion)
  • 5.4. Chemotherapy
    • 5.4.1. Chemotherapy Market, 2021 - 2033 (USD Billion)
  • 5.5. Targeted Therapy
    • 5.5.1. Targeted Therapy Market, 2021 - 2033 (USD Billion)
  • 5.6. Immunotherapy
    • 5.6.1. Immunotherapy Market, 2021 - 2033 (USD Billion)
  • 5.7. Others
    • 5.7.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 6. Non-small Cell Lung Cancer Therapeutics Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2025 & 2033
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Billion)
  • 6.4. Hospital Pharmacy
    • 6.4.1. Hospital Pharmacy Market, 2021 - 2033 (USD Billion)
  • 6.5. Drug Store and Retail Pharmacy
    • 6.5.1. Drug Store and Retail Pharmacy Market, 2021 - 2033 (USD Billion)
  • 6.6. Online Pharmacy
    • 6.6.1. Online Pharmacy Market, 2021 - 2033 (USD Billion)

Chapter 7. Non-small Cell Lung Cancer Therapeutics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. Canada Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5. Europe
    • 7.5.1. Europe Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. UK Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Target Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Target Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.7. Latin America
    • 7.7.1. Latin America Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Target Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Brazil Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Target Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. Argentina Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Target Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Target Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Target Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Target Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. AstraZeneca PLC
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Merck & Co., Inc.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. F. Hoffmann-La Roche Ltd.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Bristol Myers Squibb.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Johnson & Johnson
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Pfizer Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Novartis AG
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Eli Lilly and Company
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. GSK plc
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Boehringer Ingelheim
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
Show more
Product Code: GVR-1-68038-703-2

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global non-small cell lung cancer therapeutics market, by region, 2021 - 2033 (USD Billion)
  • Table 4 Global non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 5 Global non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 6 Global non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 7 North America non-small cell lung cancer therapeutics market, by country, 2021 - 2033 (USD Billion)
  • Table 8 North America non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 9 North America non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 10 North America non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 11 U.S. non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 12 U.S. non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 13 U.S. non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 14 Canada non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 15 Canada non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 16 Canada non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 17 Mexico non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 18 Mexico non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 19 Mexico non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 20 Europe non-small cell lung cancer therapeutics market, by country, 2021 - 2033 (USD Billion)
  • Table 21 Europe non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 22 Europe non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 23 Europe non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 24 UK non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 25 UK non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 26 UK non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 27 Germany non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 28 Germany non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 29 Germany non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 30 France non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 31 France non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 32 France non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 33 Italy non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 34 Italy non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 35 Italy non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 36 Spain non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 37 Spain non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 38 Spain non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 39 Norway non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 40 Norway non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 41 Norway non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 42 Denmark non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 43 Denmark non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 44 Denmark non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 45 Sweden non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 46 Sweden non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 47 Sweden non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 48 Asia Pacific non-small cell lung cancer therapeutics market, by country, 2021 - 2033 (USD Billion)
  • Table 49 Asia Pacific non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 50 Asia Pacific non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 51 Asia Pacific non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 52 Japan non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 53 Japan non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 54 Japan non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 55 China non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 56 China non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 57 China non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 58 India non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 59 India non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 60 India non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 61 Australia non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 62 Australia non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 63 Australia non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 64 South Korea non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 65 South Korea non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 66 South Korea non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 67 Thailand non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 68 Thailand non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 69 Thailand non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 70 Latin America non-small cell lung cancer therapeutics market, by country, 2021 - 2033 (USD Billion)
  • Table 71 Latin America non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 72 Latin America non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 73 Latin America non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 74 Brazil non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 75 Brazil non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 76 Brazil non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 77 Argentina non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 78 Argentina non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 79 Argentina non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 80 Middle East & Africa non-small cell lung cancer therapeutics market, by country, 2021 - 2033 (USD Billion)
  • Table 81 Middle East & Africa non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 82 Middle East & Africa non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 83 Middle East & Africa non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 84 South Africa non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 85 South Africa non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 86 South Africa non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 87 Saudi Arabia non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 88 Saudi Arabia non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 89 Saudi Arabia non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 90 UAE non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 91 UAE non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 92 UAE non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 93 Kuwait non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 94 Kuwait non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 95 Kuwait non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 Non-small cell lung cancer therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Non-small cell lung cancer therapeutics market dynamics
  • Fig. 11 Non-small cell lung cancer therapeutics market: Porter's five forces analysis
  • Fig. 12 Non-small cell lung cancer therapeutics market: PESTLE analysis
  • Fig. 13 Type market, 2021 - 2033 (USD Billion)
  • Fig. 14 Squamous cell carcinoma market, 2021 - 2033 (USD Billion)
  • Fig. 15 Large cell carcinoma market, 2021 - 2033 (USD Billion)
  • Fig. 16 Adenocarcinoma market, 2021 - 2033 (USD Billion)
  • Fig. 17 Others market, 2021 - 2033 (USD Billion)
  • Fig. 18 Treatment market, 2021 - 2033 (USD Billion)
  • Fig. 19 Chemotherapy market, 2021 - 2033 (USD Billion)
  • Fig. 20 Targeted therapy market, 2021 - 2033 (USD Billion)
  • Fig. 21 Immunotherapy market, 2021 - 2033 (USD Billion)
  • Fig. 22 Others market, 2021 - 2033 (USD Billion)
  • Fig. 23 Distribution channel market, 2021 - 2033 (USD Billion)
  • Fig. 24 Hospital pharmacy market, 2021 - 2033 (USD Billion)
  • Fig. 25 Drug store and retail pharmacy market, 2021 - 2033 (USD Billion)
  • Fig. 26 Online pharmacy market, 2021 - 2033 (USD Billion)
  • Fig. 27 Non-small cell lung cancer therapeutics market revenue, by region
  • Fig. 28 Regional marketplace: Key takeaways
  • Fig. 29 North America non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 30 U.S. country dynamics
  • Fig. 31 U.S. non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 32 Canada country dynamics
  • Fig. 33 Canada non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 34 Mexico country dynamics
  • Fig. 35 Mexico non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 36 Europe non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 37 UK country dynamics
  • Fig. 38 UK non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 39 Germany country dynamics
  • Fig. 40 Germany non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 41 France country dynamics
  • Fig. 42 France non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 43 Italy country dynamics
  • Fig. 44 Italy non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 45 Spain country dynamics
  • Fig. 46 Spain non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 47 Norway country dynamics
  • Fig. 48 Norway non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 49 Sweden country dynamics
  • Fig. 50 Sweden non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 51 Denmark country dynamics
  • Fig. 52 Denmark non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 53 Asia Pacific non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 54 Japan country dynamics
  • Fig. 55 Japan non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 56 China country dynamics
  • Fig. 57 China non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 58 India country dynamics
  • Fig. 59 India non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 60 Australia country dynamics
  • Fig. 61 Australia non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 62 South Korea country dynamics
  • Fig. 63 South Korea non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 64 Thailand country dynamics
  • Fig. 65 Thailand non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 66 Latin America non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 67 Brazil country dynamics
  • Fig. 68 Brazil non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 69 Argentina country dynamics
  • Fig. 70 Argentina non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 71 MEA non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 72 South Africa country dynamics
  • Fig. 73 South Africa non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 74 Saudi Arabia country dynamics
  • Fig. 75 Saudi Arabia non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 76 UAE country dynamics
  • Fig. 77 UAE non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 78 Kuwait country dynamics
  • Fig. 79 Kuwait non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 80 Company categorization
  • Fig. 81 Company market position analysis
  • Fig. 82 Strategic framework
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!